share_log

Pediatrix Medical Group Insiders Sold US$957k Of Shares Suggesting Hesitancy

Simply Wall St ·  Mar 13 09:30

Pediatrix Medical Group, Inc. (NYSE:MD) shareholders may have reason to be concerned, as several insiders sold their shares over the past year. When evaluating insider transactions, knowing whether insiders are buying versus if they selling is usually more beneficial, as the latter can be open to many interpretations. However, shareholders should take a deeper look if several insiders are selling stock over a specific time period.

While insider transactions are not the most important thing when it comes to long-term investing, we would consider it foolish to ignore insider transactions altogether.

Pediatrix Medical Group Insider Transactions Over The Last Year

Over the last year, we can see that the biggest insider sale was by the Chair, Mark Ordan, for US$438k worth of shares, at about US$13.26 per share. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. The good news is that this large sale was at well above current price of US$9.36. So it is hard to draw any strong conclusion from it.

Pediatrix Medical Group insiders didn't buy any shares over the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

insider-trading-volume
NYSE:MD Insider Trading Volume March 13th 2024

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Insiders At Pediatrix Medical Group Have Sold Stock Recently

Over the last three months, we've seen significant insider selling at Pediatrix Medical Group. Specifically, insiders ditched US$76k worth of shares in that time, and we didn't record any purchases whatsoever. Overall this makes us a bit cautious, but it's not the be all and end all.

Insider Ownership Of Pediatrix Medical Group

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. I reckon it's a good sign if insiders own a significant number of shares in the company. From our data, it seems that Pediatrix Medical Group insiders own 1.0% of the company, worth about US$7.3m. Whilst better than nothing, we're not overly impressed by these holdings.

So What Do The Pediatrix Medical Group Insider Transactions Indicate?

Insiders sold stock recently, but they haven't been buying. And even if we look at the last year, we didn't see any purchases. When you combine this with the relatively low insider ownership, we are very cautious about the stock. So we're not rushing to buy, to say the least. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. In terms of investment risks, we've identified 1 warning sign with Pediatrix Medical Group and understanding this should be part of your investment process.

But note: Pediatrix Medical Group may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment